A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Public ClinicalTrials.gov record NCT00833417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pivotal Phase II, Multicenter, Single-arm, Two-cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma
Study identification
- NCT ID
- NCT00833417
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Interventions
- Vismodegib 150 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 9, 2009
- Primary completion
- Nov 25, 2010
- Completion
- Apr 8, 2014
- Last update posted
- May 10, 2026
2009 – 2014
United States locations
- U.S. sites
- 21
- U.S. states
- 18
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| Angeles Clinic & Rsch Inst | Los Angeles | California | 90025 | — |
| Stanford University Medical Center | Palo Alto | California | 94304 | — |
| Univ of Calif-San Francisco | San Francisco | California | 94115 | — |
| Univ of Colorado Hlth Sci Ctr | Aurora | Colorado | 80045 | — |
| Advanced Derm & Cosmetic Surg | Ormond Beach | Florida | 32174 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Siouxland Hematology/Oncology | Sioux City | Iowa | 51101 | — |
| Johns Hopkins Univ Med Center | Baltimore | Maryland | 21231 | — |
| Massachusetts General Hospital. | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic Rochester; Medical Oncology | Rochester | Minnesota | 55905 | — |
| VA Southern Nevada Healthcare | Las Vegas | Nevada | 89103 | — |
| Dartmouth Hitchcock Med Center | Lebanon | New Hampshire | 03756 | — |
| Mount Sinai School of Medicine; Dermatology | New York | New York | 10029 | — |
| Univ No Carolina School of Med; Physicians Office Bldg | Chapel Hill | North Carolina | 27599-7305v | — |
| Arthur G. James Cancer Hosp | Columbus | Ohio | 43210 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| The Sarah Cannon Research Inst | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030-4095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00833417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 10, 2026 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00833417 live on ClinicalTrials.gov.